Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics

References

• Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. doi:10.1016/j.jaad.2019.08.049
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023;22(1):25–41. PMID: 36718762. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023;22(1):43–58. PMID: 36718748.. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cacciapuoti S, Cinelli E, Gallo L, Megna M. Ocular manifestations in psoriasis screening (OcMaPS) questionnaire: a useful tool to reveal misdiagnosed ocular involvement in psoriasis. J Clin Med. 2021;10(5):1031. doi:10.3390/jcm10051031
   PubMed Web of Science ®Google Scholar
• Kwon HH, Na SJ, Jo SJ, et al. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol. 2012;39(3):260–264. doi:10.1111/j.1346-8138.2011.01452.x
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi:10.1016/j.jaad.2016.07.064
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study. Dermatol Ther. 2022;35(1):e15214. PMID: 34800070; PMCID: PMC9285826. doi:10.1111/dth.15214
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. PMID: 35439341; PMCID: PMC9539505.. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Napolitano M, Megna M, Balato A, et al. Systemic treatment of pediatric psoriasis: a review. Dermatol Ther. 2016;6(2):125–142.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin CosmetInvestig Dermatol. 2022;15:1649–1658. PMID: 35996400; PMCID: PMC9392468.. doi:10.2147/CCID.S364640
   Google Scholar
• Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280–2282. PMID: 35867020; PMCID: PMC9349949. doi:10.1111/ced.15336
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, Marano L, Fabbrocini G, Marasca C. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review. Biomedicines. 2022;10(2):455. PMID: 35203664; PMCID: PMC8962303.. doi:10.3390/biomedicines10020455
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62(1):114–135. doi:10.1016/j.jaad.2009.08.026
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Annunziata MC, Fabbrocini G, Megna M. Face the COVID-19 emergency: measures applied in an Italian Dermatologic Clinic. J Eur Acad Dermatol Venereol. 2020;34(6):e249. PMID: 32294282; PMCID: PMC7262301. doi:10.1111/jdv.16476
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Fabbrocini G, Ruggiero A. Strategies adopted in a southern Italian referral centre to reduce Adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’. Clin Exp Dermatol. 2022;47(10):1864–1865. doi:10.1111/ced.15291
   PubMed Web of Science ®Google Scholar
• Ersoy-Evans S, Altaykan A, Sahin S, Kölemen F. Phototherapy in childhood. Pediatr Dermatol. 2008;25(6):599–605. PMID: 19067863. doi:10.1111/j.1525-1470.2008.00773.x
   PubMed Web of Science ®Google Scholar
• Bronckers IM, Seyger MMB, West DP, et al. Psoriasis Investigator Group (PsIG) of the Pediatric Dermatology Research Alliance and the European Working Group on Pediatric Psoriasis (EWGPP). Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153(11):1147–1157. PMID: 28903160; PMCID: PMC5710436. doi:10.1001/jamadermatol.2017.3029
   PubMed Web of Science ®Google Scholar
• Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol. 1996;21(6):399–408. PMID: 9167333. doi:10.1111/j.1365-2230.1996.tb00142.x
   PubMed Web of Science ®Google Scholar
• van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. Systemic treatments in paediatric psoriasis: a systematic evidence-based update. J EurAcad Dermatol Venereol. 2015;29(3):425–437. PMID: 25346019. doi:10.1111/jdv.12749
   PubMed Web of Science ®Google Scholar
• Collin B, Vani A, Ogboli M, Moss C. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol. 2009;34(3):295–298. PMID: 19175782. doi:10.1111/j.1365-2230.2008.02907.x
   PubMed Web of Science ®Google Scholar
• Kaur I, Dogra S, De D, Kanwar AJ. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol. 2008;25(2):184–188. PMID: 18429775. doi:10.1111/j.1525-1470.2008.00629.x
   PubMed Web of Science ®Google Scholar
• Bedoui Y, Guillot X, Sélambarom J, et al. Methotrexate an old drug with new tricks. Int J Mol Sci. 2019;20(20):5023. PMID: 31658782; PMCID: PMC6834162. doi:10.3390/ijms20205023
   PubMed Web of Science ®Google Scholar
• Fradin MS, Ellis CN, Voorhees JJ. Efficacy of cyclosporin A in psoriasis: a summary of the United States’ experience. Br J Dermatol. 1990;122:21–25. PMID: 2196080. doi:10.1111/j.1365-2133.1990.tb02878.x
   PubMed Web of Science ®Google Scholar
• Bulbul Baskan E, Yazici S, Tunali S, Saricaoglu H. Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis. J Dermatolog Treat. 2016;27(4):328–331. PMID: 26651208. doi:10.3109/09546634.2015.1115813
   PubMed Web of Science ®Google Scholar
• Dogra S, Mahajan R, Narang T, Handa S. Systemic cyclosporine treatment in severe childhood psoriasis: a retrospective chart review. J Dermatolog Treat. 2017;28(1):18–20. PMID: 27771982. doi:10.3109/09546634.2015.1034072
   PubMed Web of Science ®Google Scholar
• Kiliç SS, Hacimustafaoğlu M, Celebi S, Karadeniz A, Ildirim I. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol. 2001;18(3):246–248. PMID: 11438009. doi:10.1046/j.1525-1470.2001.018003246.x
   PubMed Web of Science ®Google Scholar
• Chao PH, Cheng YW, Chung MY. Generalized pustular psoriasis in a 6-week-old infant. Pediatr Dermatol. 2009;26(3):352–354. PMID: 19706107. doi:10.1111/j.1525-1470.2009.00918.x
   PubMed Web of Science ®Google Scholar
• Popadic S, Nikolic M. Pustular psoriasis in childhood and adolescence: a 20-year single-center experience. PediatrDermatol. 2014;31:575–579.
   Google Scholar
• Chen P, Li C, Xue R, et al. Efficacy and safety of Acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review. J Dermatolog Treat. 2018;29:353–363. doi:10.1080/09546634.2017.1395798
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22(12):1431–1433. PMID: 35968665. doi:10.1080/14712598.2022.2113872
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Investig Dermatol. 2023;16:529–536. doi:10.2147/CCID.S402183
   PubMed Web of Science ®Google Scholar
• Dunn LK, Gaar LR, Yentzer BA, O’Neill JL, Feldman SR. Acitretin in dermatology: a review. J Drugs Dermatol. 2011;10(7):772–782. PMID: 21720660.
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris. J EurAcad Dermatol Venereol. 2020;34:2461–2498. doi:10.1111/jdv.16915
   PubMed Web of Science ®Google Scholar
• Bronckers I, Seyger MMB, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153:1147–1157. doi:10.1001/jamadermatol.2017.3029
   PubMed Web of Science ®Google Scholar
• Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297. doi:10.3390/ijms18112297
   PubMed Web of Science ®Google Scholar
• Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of Adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241–251. doi:10.1016/j.jaad.2010.12.005
   PubMed Web of Science ®Google Scholar
• Zangrilli A, Bavetta M, Bianchi L. Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation. Expert Opin Drug Saf. 2020;19(4):433–438. doi:10.1080/14740338.2020.1752659
   PubMed Web of Science ®Google Scholar
• Papp K, Thaci D, Marcoux D, et al. Efficacy and safety of Adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10089):40–49. doi:10.1016/S0140-6736(17)31189-3
   PubMed Web of Science ®Google Scholar
• Thaci D, Papp K, Marcoux D, et al. Sustained long-term efficacy and safety of Adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermtol. 2019;181(6):1177–1189. doi:10.1111/bjd.18029
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of Adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566. doi:10.1111/j.1365-2133.2007.08315.x
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241–251. doi:10.1056/NEJMoa066886
   PubMed Web of Science ®Google Scholar
• Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64:64–70. doi:10.1016/j.jaad.2010.02.060
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63:762–768. doi:10.1016/j.jaad.2010.04.004
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74:280–287. doi:10.1016/j.jaad.2015.09.056
   PubMed Web of Science ®Google Scholar
• Kivelevitch D, Mansouri B, Menter A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics. 2014;8:169–182. doi:10.2147/BTT.S41481
   PubMedGoogle Scholar
• Subedi S, Gong Y, Chen Y, Shi Y. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug DesDevel Ther. 2019;13:2491–2502. doi:10.2147/DDDT.S200147
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850. doi:10.1016/j.jaad.2008.02.039
   PubMed Web of Science ®Google Scholar
• Brownstone ND, Hong J, Mosca M, et al. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021;15:39–51.
   PubMed Web of Science ®Google Scholar
• Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482. doi:10.3390/biomedicines9101482
   PubMed Web of Science ®Google Scholar
• Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–233. doi:10.1136/annrheumdis-2017-212196
   PubMed Web of Science ®Google Scholar
• Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890–1896. doi:10.1136/annrheumdis-2017-211384
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebocontrolled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79(2):302–314.e6. doi:10.1016/j.jaad.2018.04.012
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Orlando A, Cottone M. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn’s disease. Expert Opin Biol Ther. 2019;19(2):89–98. doi:10.1080/14712598.2019.1561850
   PubMed Web of Science ®Google Scholar
• Savage LJ, Wittmann M, McGonagle D, Helliwell PS. Ustekinumab in the treatment of psoriasis and psoriatic arthritis. Rheumatol Ther. 2015;2(1):1–16. doi:10.1007/s40744-015-0010-2
   PubMedGoogle Scholar
• Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603. doi:10.1016/j.jaad.2015.07.002
   PubMed Web of Science ®Google Scholar
• Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183(4):664–672. doi:10.1111/bjd.19018
   PubMed Web of Science ®Google Scholar
• Yang JE, Beck KM, Liao W. Secukinumab in the treatment of psoriasis: patient selection and perspectives. Psoriasis. 2018;8:75–82. doi:10.2147/PTT.S146004
   PubMed Web of Science ®Google Scholar
• Fauny M, Moulin D, D’Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79:1132–1138. doi:10.1136/annrheumdis-2020-217927
   PubMed Web of Science ®Google Scholar
• Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47–62. doi:10.1111/bjd.15015
   PubMed Web of Science ®Google Scholar
• Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial. J EurAcad Dermatol Venereol. 2020;35(4):938–947. doi:10.1111/jdv.17002
   Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Megna M, Annunziata MC, Fabbrocini G. Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy. J Dermatolog Treat. 2022;33(1):592. doi:10.1080/09546634.2020.1769828
   PubMed Web of Science ®Google Scholar
• Magnolo N, Kingo K, Laquer V, et al. A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2021;85:AB119. doi:10.1016/j.jaad.2021.06.493
   Web of Science ®Google Scholar
• Reich A, Magnolo N, Kingo K, et al. Secukinumab treatment demonstrated high efficacy and safety in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from a randomised trial. Pediatr Dermatol. 2021;38(Suppl. 1):57–58.
   Google Scholar
• Zagaria O, Villani A, Ruggiero A, Potestio L, Fabbrocini G, Gallo L. New-onset lichen planus arising after COVID-19 vaccination. Dermatol Ther. 2022;35(5):e15374. doi:10.1111/dth.15374
   PubMed Web of Science ®Google Scholar
• Azevedo A, Torres T. Clinical efficacy and safety of ixekizumab for treatment of psoriasis. ActasDermosifiliogr. 2017;108(4):305–314.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Burlando M, Caldarola G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441–447. doi:10.1007/s40257-019-00490-2
   PubMed Web of Science ®Google Scholar
• Paller AS, Seyger MMB, Magariños GA, et al. IXORA-PEDS investigators. long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. 2022;158(5):533–541. doi:10.1001/jamadermatol.2022.0655
   PubMed Web of Science ®Google Scholar
• Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8(212570):1–11. doi:10.7573/dic.212570
   Google Scholar
• Lebwohl MG, Blauvelt A, Menter A, et al. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with brodalumab for 5 years in a long-term, open-label, phase II study. Am J Clin Dermatol. 2019;20(6):863–871. doi:10.1007/s40257-019-00466-2
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
   PubMed Web of Science ®Google Scholar
• Oliver R, Krueger JG, Glatt S, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022;186(4):652–663. doi:10.1111/bjd.20827
   PubMed Web of Science ®Google Scholar
• Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–486. doi:10.1016/S0140-6736(21)00126-4
   PubMed Web of Science ®Google Scholar
• Megna M, Caiazzo G, Parisi M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? Clin Exp Dermatol. 2022;47(5):918–925. doi:10.1111/ced.15052
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Papp KA, Lynde CW. Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders. J EurAcad Dermatol Venereol. 2018;32(7):1111–1119. doi:10.1111/jdv.14868
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605–1613. doi:10.4049/jimmunol.1800013
   PubMed Web of Science ®Google Scholar
• Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–119. doi:10.1177/2040622318759282
   PubMed Web of Science ®Google Scholar
• Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2020;21:1–20. doi:10.1007/s40257-019-00475-1
   PubMedGoogle Scholar
• Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Targeting IL-23 in psoriasis: current perspectives. Psoriasis. 2018;8:1–5. doi:10.2147/PTT.S98893
   PubMed Web of Science ®Google Scholar
• Potestio L, Genco L, Villani A, et al. Reply to ‘Cutaneous adverse effects of the available COVID-19 vaccines in India: a questionnaire-based study’ by Bawane J et al. J Eur Acad Dermatol Venereol. 2022;36(11):e863–e864. doi:10.1111/jdv.18341
   PubMed Web of Science ®Google Scholar
• Schmitt H, Neurath MF, Atreya R. Role of the IL23/IL17 Pathway in Crohn’s Disease. Front Immunol. 2021;12:622934. PMID: 33859636; PMCID: PMC8042267. doi:10.3389/fimmu.2021.622934
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guselkumab (tremfya)_Summary of Product Characteristics_EMA; 2017. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya. Accessed November 02, 2023.
   Google Scholar
• Light JG, Su JJ, Feldman SR. Clinical utility of guselkumab in the treatment of moderate-to-severe plaque psoriasis. Clin CosmetInvestig Dermatol. 2021;14:55–63.
   Google Scholar
• Nakamura M, Lee K, Jeon C, et al. Guselkumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther. 2017;7(3):281–292. doi:10.1007/s13555-017-0187-0
   PubMed Web of Science ®Google Scholar
• Nogueira M, Torres T. Guselkumab for the treatment of psoriasis – evidence to date. Drugs Context. 2019;8:212594. doi:10.7573/dic.212594
   PubMedGoogle Scholar
• Kim SR, Kibbi N, Craiglow BG. Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient. JAAD Case Rep. 2019;5(6):552–554. PMID: 31245518; PMCID: PMC6581971. doi:10.1016/j.jdcr.2019.04.014
   PubMedGoogle Scholar
• Song EJ, Whitman P, Samsel J. The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection. JAAD Case Rep. 2020;8:37–39. PMID: 33490344; PMCID: PMC7806953. doi:10.1016/j.jdcr.2020.12.006
   PubMedGoogle Scholar
• European Medicines Agency. Tildrakizumab (ilumetri)_Summary of Product Characteristics_EMA; 2018. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri. Accessed November 02, 2023.
   Google Scholar
• Igarashi A, Nakagawa H, Morita A, et al. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaquepsoriasis: results from a 64-week phase 3 study (reSURFACE 1). J Dermatol. 2021;48(6):853–863. doi:10.1111/1346-8138.15789
   PubMed Web of Science ®Google Scholar
• Näslund-Koch C, Zachariae C, Skov L. Tildrakizumab: an evidence- based review of its use in the treatment of moderate-to-severe chronic plaque psoriasis. Ther Clin Risk Manag. 2020;16:903–916. doi:10.2147/TCRM.S227880
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Iversen L, et al. Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605–617. doi:10.1111/bjd.18232
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Risankizumab (skyrizi)_Summary of Product Characteristics_EMA; 2019. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi. Accessed November 02, 2023.
   Google Scholar
• Haugh IM, Preston AK, Kivelevitch DN, Menter AM. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther. 2018;12:3879–3883. doi:10.2147/DDDT.S167149
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023;22(5):355–362. doi:10.1080/14740338.2023.2218086
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi:10.1016/S0140-6736(18)31713-6
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Del-Alcazar E. Apremilast for psoriasis treatment. G Ital Dermatol Venereol. 2020;155(4):421–433. PMID: 32545946. doi:10.23736/S0392-0488.20.06684-5
   PubMed Web of Science ®Google Scholar
• Raker VK, Becker C, Steinbrink K. The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases. Front Immunol. 2016;7:123. doi:10.3389/fimmu.2016.00123
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/otezla-epar-product-information_it.pdf. Accessed January 07, 2023.
   Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a Phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49. doi:10.1016/j.jaad.2015.03.049
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387–1399. doi:10.1111/bjd.14164
   PubMed Web of Science ®Google Scholar
• Stein Gold L, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in systemic- And biologic-naive patients with moderate plaque psoriasis: 52-week results of UnVEIL. J Drugs Dermatol. 2018;17:221–228.
   PubMed Web of Science ®Google Scholar
• Strober B, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the unveil study. J Drugs Dermatol. 2017;16:801–808.
   PubMed Web of Science ®Google Scholar
• Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77:310–317.e1. doi:10.1016/j.jaad.2017.01.052
   PubMed Web of Science ®Google Scholar
• Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891–895. doi:10.1001/archdermatol.2010.186
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Fabbrocini G, et al. The role of teledermatology during the COVID-19 pandemic: a narrative review. Clin Cosmet Investig Dermatol. 2022;15:2785–2793. doi:10.2147/CCID.S377029
   PubMed Web of Science ®Google Scholar
• Lamb RC, Matcham F, Turner MA, et al. Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol. 2017;176:1028–1034. doi:10.1111/bjd.14833
   PubMed Web of Science ®Google Scholar
• Lakshmy S, Balasundaram S, Sarkar S, Audhya M, Subramaniam E. A cross-sectional study of prevalence and implications of depression and anxiety in psoriasis. Indian J Psychol Med. 2015;37:434–440. doi:10.4103/0253-7176.168587
   PubMedGoogle Scholar
• Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a Phase 2 open-label study. J Am Acad Dermatol. 2020;82(2):389–397. doi:10.1016/j.jaad.2019.08.019
   PubMed Web of Science ®Google Scholar